PolyPeptide Group · ISIN: CH1110760852 · EQS - Company News

Large-scale SPPS capacity in Braine-l’Alleud starts production

PolyPeptide Group / Key word(s): Miscellaneous Large-scale SPPS capacity in Braine-l’Alleud starts production 16.12.2024 / 07:00 CET/CEST Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the new large-scale SPPS capacity at its manufacturing site in Braine-l’Alleud, B...

SIX:PPGN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News PolyPeptide Group

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
16 December 2024 07:00AM
Large-scale SPPS capacity in Braine-l’Alleud starts production
CH1110760852
PolyPeptide Group / Key word(s): Miscellaneous Large-scale SPPS capacity in Braine-l’Alleud starts production 16.12.2024 / 07:00 CET/CEST Media release Large-scale SPPS capacity in Braine-l’Alleud starts production Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based activ...
PolyPeptide Group
About the publication
13 August 2024 07:00AM
Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028 Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results f...
PolyPeptide Group
About the publication
08 August 2024 08:00PM
PolyPeptide appoints Chief Commercial Officer
CH1110760852
PolyPeptide Group / Key word(s): Personnel PolyPeptide appoints Chief Commercial Officer 08.08.2024 / 20:00 CET/CEST Media release PolyPeptide appoints Chief Commercial Officer Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ing...
PolyPeptide Group
About the publication
10 April 2024 07:23PM
PolyPeptide announces results of the annual General Meeting 2024
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide announces results of the annual General Meeting 2024 10.04.2024 / 19:23 CET/CEST Media release PolyPeptide announces results of the annual General Meeting 2024 Baar, 10 April 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleot...
PolyPeptide Group
About the publication
19 March 2024 07:00AM
PolyPeptide publishes invitation to the annual General Meeting 2024
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2024 19.03.2024 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2024 Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligon...
PolyPeptide Group
About the publication
12 March 2024 06:45AM
PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR   PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical in...
PolyPeptide Group
About the publication
31 October 2023 07:00AM
PolyPeptide signs scientific collaboration agreement
CH1110760852
PolyPeptide Group / Key word(s): Partnership/ESG PolyPeptide signs scientific collaboration agreement 31.10.2023 / 07:00 CET/CEST Media Release                             PolyPeptide signs scientific collaboration agreement Strasbourg, 31 October 2023 – PolyPeptide today announced the signing of a collaboration agre...
PolyPeptide Group
About the publication
02 October 2023 07:00AM
PolyPeptide secures revolving credit facility
CH1110760852
PolyPeptide Group / Key word(s): Financing PolyPeptide secures revolving credit facility 02.10.2023 / 07:00 CET/CEST Media Release PolyPeptide secures revolving credit facility Baar, 2 October 2023 – PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit S...
PolyPeptide Group
About the publication
15 August 2023 07:00AM
Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported re...
PolyPeptide Group
About the publication
13 July 2023 07:00AM
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR  PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023 Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide business. It expects 2023 to be ...
PolyPeptide Group
About the publication
13 July 2023 07:00AM
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR  PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023 Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide business. It expects 2023 to be ...
PolyPeptide Group
About the publication
09 May 2023 08:40PM
PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs
CH1110760852
PolyPeptide Group / Key word(s): Partnership PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs 09.05.2023 / 20:40 CET/CEST Media release            PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable ...
PolyPeptide Group
About the publication
09 May 2023 08:40PM
PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs
CH1110760852
PolyPeptide Group / Key word(s): Partnership PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs 09.05.2023 / 20:40 CET/CEST Media release            PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable ...
PolyPeptide Group
About the publication
12 April 2023 07:18PM
PolyPeptide announces results of the annual General Meeting 2023
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide announces results of the annual General Meeting 2023 12.04.2023 / 19:18 CET/CEST Media Release   PolyPeptide announces results of the annual General Meeting 2023   Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-...
PolyPeptide Group
About the publication
12 April 2023 07:18PM
PolyPeptide announces results of the annual General Meeting 2023
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide announces results of the annual General Meeting 2023 12.04.2023 / 19:18 CET/CEST Media Release   PolyPeptide announces results of the annual General Meeting 2023   Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-...
PolyPeptide Group
About the publication
03 April 2023 07:00AM
PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                         PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Jua...
PolyPeptide Group
About the publication
03 April 2023 07:00AM
PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                         PolyPeptide appoints Juan-José Gonzalez as CEO and announces change of CFO Baar, 3 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the appointment of Jua...
PolyPeptide Group
About the publication
22 March 2023 07:00AM
PolyPeptide publishes invitation to the annual General Meeting 2023
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2023 22.03.2023 / 07:00 CET/CEST Media releasePolyPeptide publishes invitation to the annual General Meeting 2023 Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-bas...
PolyPeptide Group
About the publication
22 March 2023 07:00AM
PolyPeptide publishes invitation to the annual General Meeting 2023
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2023 22.03.2023 / 07:00 CET/CEST Media releasePolyPeptide publishes invitation to the annual General Meeting 2023 Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-bas...
PolyPeptide Group
About the publication
14 March 2023 07:00AM
PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023 Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its...
PolyPeptide
About the publication
14 March 2023 07:00AM
PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023
CH1110760852
Media release – ad hoc announcement pursuant to Art. 53 LR                PolyPeptide reports weaker performance in 2022 – expects growth to recover in the second half of 2023 Baar, 14 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced its...
PolyPeptide
About the publication
30 January 2023 07:00AM
CEO of PolyPeptide resigns
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                          CEO of PolyPeptide resigns Baar, 30 January 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the resignation by its CEO Raymond De Vré.   Raymond De Vré, CEO ...
PolyPeptide
About the publication
19 December 2022 07:00AM
PolyPeptide signs significant commercial agreement
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                         PolyPeptide signs significant commercial agreement   Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial a...
PolyPeptide
About the publication
19 December 2022 07:00AM
PolyPeptide signs significant commercial agreement
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                         PolyPeptide signs significant commercial agreement   Baar, 19 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today announced the signing of a significant commercial a...
PolyPeptide
About the publication
02 December 2022 07:00AM
PolyPeptide provides market update
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR  PolyPeptide provides market update Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. Audio webcast scheduled for today at 09.30 am CET.   Several op...
PolyPeptide
About the publication
02 December 2022 07:00AM
PolyPeptide provides market update
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR  PolyPeptide provides market update Baar, 2 December 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients, today provided a market update. Audio webcast scheduled for today at 09.30 am CET.   Several op...
PolyPeptide
About the publication
19 August 2022 07:00AM
PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                           PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022 Baar, 19 August 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active phar...
PolyPeptide Group
About the publication
19 August 2022 07:00AM
PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                           PolyPeptide with encouraging progress within custom projects pipeline – however with lower profitability in the first half of 2022 Baar, 19 August 2022 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligo-nucleotide-based active phar...
PolyPeptide Group
About the publication
12 July 2022 07:00AM
PolyPeptide Group provides market update
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                                       PolyPeptide provides market update Baar, 12 July 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide and oligonucleotide development and manufacturing, today provides a market update. While investing to implement its growth strategy...
PolyPeptide Group
About the publication
12 July 2022 07:00AM
PolyPeptide Group provides market update
CH1110760852
Media Release – ad hoc announcement pursuant to Art. 53 LR                                       PolyPeptide provides market update Baar, 12 July 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide and oligonucleotide development and manufacturing, today provides a market update. While investing to implement its growth strategy...
PolyPeptide Group
About the publication
09 May 2022 07:00AM
Monika Casanova joining PolyPeptide as CHRO and member of the PMC
CH1110760852
PolyPeptide Group / Key word(s): Personnel PolyPeptide Group: Monika Casanova joining PolyPeptide as CHRO and member of the PMC 09.05.2022 / 07:00 Monika Casanova joining PolyPeptide as CHRO and member of the PMC Baar, 9 May 2022 – PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, tod...
PolyPeptide Group
About the publication
26 April 2022 06:00PM
PolyPeptide Group announces results of the annual General Meeting 2022
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide Group announces results of the annual General Meeting 2022 26.04.2022 / 18:00 PolyPeptide announces results of the annual General Meeting 2022 Zug, 26 April 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced tha...
PolyPeptide Group
About the publication
01 April 2022 07:00AM
PolyPeptide publishes invitation to the annual General Meeting 2022
CH1110760852
PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2022 01.04.2022 / 07:00 PolyPeptide publishes invitation to the annual General Meeting 2022 Zug, 1 April 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published tod...
PolyPeptide Group
About the publication
15 March 2022 07:00AM
PolyPeptide achieves strong profitable growth in 2021
CH1110760852
Media Release - ad hoc announcement pursuant to Art. 53 LR PolyPeptide achieves strong profitable growth in 2021 Zug, 15 March 2022 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021: - Revenue growth of 26.5% year-over-year to EUR 282.1 mil...
PolyPeptide Group
About the publication
01 December 2021 07:00AM
PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
CH1110760852
Media Release - ad hoc announcement pursuant to Art. 53 LR PolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen Zug, December 1, 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil...
PolyPeptide Group
About the publication
10 November 2021 07:15AM
Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
CH1110760852
Media Release Ad hoc announcement pursuant to Art. 53 LR Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG Zug, 10 November 2021 - PolyPeptide Group AG ("PolyPeptide") has been informed that Draupnir Holding B.V. ("Draupnir"), which held 60.0% of PolyPeptide's share capital as of close of trading on S...
PolyPeptide Group
About the publication
17 August 2021 07:00AM
PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
CH1110760852
Media Release - ad hoc announcement pursuant to Art. 53 LR PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends Zug, 17 August 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results...
PolyPeptide Group
About the publication
25 June 2021 07:00AM
PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
CH1110760852
Media Release - ad hoc announcement pursuant to Art. 53 LR PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee Zug, 25 June 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and mem...
PolyPeptide Group
About the publication
05 May 2021 05:40PM
PolyPeptide Group announces the exercise of the full over-allotment option
CH1110760852
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PE...
PolyPeptide Group
About the publication
More PolyPeptide Group related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN